NHS Data Platform: UK Alternatives Outperform Palantir 2026

The NHS data platform debate has taken a new turn as evidence shows that a UK-built alternative to Palantir is already outperforming the American giant. Greater Manchester’s integrated care board remains the only one in England to decline the Palantir federated data platform, relying instead on a homegrown system developed with British universities, NHS clinicians, and domestic tech firms.

Why Greater Manchester Chose a Homegrown NHS Data Platform

The decision was not about caution but bold conviction. The board concluded its own data capability was stronger than any imported solution. After nine years without Palantir, the results speak for themselves: a sovereign infrastructure that integrates seamlessly with local systems and respects patient data privacy.

This approach highlights the growing risk of excessive reliance on a small number of dominant overseas technology companies, particularly from the US. As healthcare digital transformation accelerates, the NHS must ask: if one English region can build sovereign health data infrastructure that outperforms the imported version, why can’t the country?

Comparison: Palantir vs UK-Built NHS Data Platform

Key Takeaways for NHS Decision-Makers

• Sovereign data infrastructure is not just possible—it is already running in Greater Manchester.
• Domestic alternatives reduce dependence on foreign tech giants like Palantir.
• Investment in UK companies and universities strengthens national resilience and innovation.
• Patient privacy and data security improve with local governance.
• The NHS can lead in digital health without outsourcing core capabilities.

Dr Devan Moodley, CEO of Health Connect Global, argues that Downing Street should ask a simple question: if one English region can build sovereign health data infrastructure that outperforms the imported version, why can’t the country? The domestic alternative is not hypothetical—it is already operational and delivering results.

The Risks of Over-Reliance on American Tech

The letter’s author warns that as healthcare becomes increasingly dependent on digital platforms, cloud infrastructure, AI systems, and data management technology, the risk of excessive reliance on a small number of dominant overseas companies grows. This is not anti-American sentiment; it is common sense. The NHS must prioritize UK technology vendors that understand the local system and can offer long-term value.

FAQ

As the NHS continues its digital transformation, the choice between Palantir and a UK-built alternative represents a critical fork in the road. The evidence from Greater Manchester suggests that investing in homegrown capability yields superior outcomes—both clinically and economically. The question now is whether national leaders will have the bold conviction to follow that lead.